Pancreatic Cancer Research

ResearcherUniversity of ManchesterActive in the last 2 years

Ángela Lamarca

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9696-6122; OpenAlex author ID A5087850177. Sources: OpenAlex.

Their work

Papers
22 (first author 6, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
74
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 4 papers · 2021: 4 papers · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 22

  1. Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHEIA-SEOM cohort. Co-author DOI 10.1007/s12094-026-04554-8↗
  2. Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group. Co-author DOI 10.1016/j.pan.2026.08.008↗
  3. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. First author DOI 10.2217/fon-2023-0963↗
  4. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Co-author DOI 10.1016/j.annonc.2023.08.009↗
  5. Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15030738↗
  6. Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy … Co-author DOI 10.3390/cancers15082277↗
  7. Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre. Co-author DOI 10.3390/healthcare11202802↗
  8. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2022.02.014↗
  9. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemothera… Co-author DOI 10.1080/0284186x.2022.2053198↗
  10. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ejso.2021.04.031↗
  11. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Co-author DOI 10.1038/s41467-021-27607-8↗
  12. Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy … First author DOI 10.1136/bmjopen-2020-042067↗
  13. The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. First author DOI 10.3390/cancers13153779↗
  14. The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. First author DOI 10.1016/j.pan.2020.03.020↗
  15. Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Last author DOI 10.1016/j.pan.2020.09.012↗
  16. The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000001486↗
  17. Spontaneous Aortic Haematoma in a Patient Receiving Adjuvant Folinic Acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin Chemotherapy Following Resection of a Pa… Last author DOI 10.7759/cureus.10908↗
  18. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Co-author DOI 10.1016/j.pan.2018.10.003↗
  19. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Co-author DOI 10.1038/s41598-019-47489-7↗
  20. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. First author DOI 10.4251/wjgo.v11.i2.102↗
  21. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/ijms18050909↗
  22. 18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2015.12.014↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan W. Valle · 17 shared papers, 2016–2023 · strength 2.09
  2. Mairead Geraldine McNamara · 15 shared papers, 2016–2023 · strength 1.90
  3. Richard A Hubner · 14 shared papers, 2016–2023 · strength 1.73
  4. Lindsay E. Carnie · 4 shared papers, 2020–2023 · strength 0.55
  5. Rille Pihlak · 4 shared papers, 2017–2023 · strength 0.48
  6. Alberto Carmona‐Bayonas · 2 shared papers, 2026 · strength 0.45
  7. Vilma Pacheco-Barcía · 2 shared papers, 2026 · strength 0.45
  8. Elena Brozos-Vázquez · 2 shared papers, 2026 · strength 0.45
  9. Javier Gallego-Plazas · 2 shared papers, 2026 · strength 0.45
  10. Carmen Guillén‐Ponce · 2 shared papers, 2026 · strength 0.45
  11. Arndt Vogel · 2 shared papers, 2023–2024 · strength 0.37
  12. Derek A O'Reilly · 3 shared papers, 2019–2020 · strength 0.33
  13. Nicola de Liguori Carino · 2 shared papers, 2020–2022 · strength 0.28
  14. Ismael Ghanem · 1 shared paper, 2026 · strength 0.23
  15. Andrés Jesús Muñoz Martín · 1 shared paper, 2026 · strength 0.22
  16. Luis Cabezón‐Gutiérrez · 1 shared paper, 2026 · strength 0.22
  17. Hye Jin Choi · 1 shared paper, 2024 · strength 0.20
  18. Makoto Ueno · 1 shared paper, 2024 · strength 0.20
  19. Michael Jon Pishvaian · 1 shared paper, 2024 · strength 0.20
  20. Changhoon Yoo · 1 shared paper, 2024 · strength 0.20
  21. Chigusa Morizane · 1 shared paper, 2024 · strength 0.20
  22. Simon Gray · 1 shared paper, 2022 · strength 0.17
  23. Ganesh Radhakrishna · 1 shared paper, 2022 · strength 0.17
  24. Rozana Abdul Rahman · 1 shared paper, 2021 · strength 0.17
  25. Talia Golan · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.